Background: Calfactant is an exogenous surfactant used to treat and prevent respiratory distress syndrome in the newborn infant. It is available in single-use preservative-free vials, but contains enough volume to provide multiple doses to small infants.
Objective: To measure the preservation of calfactant sterility at 12- and 24-hour intervals following initial violation of vial contents and to extrapolate cost savings associated with product conservation.
Methods: A prospective sterility study was performed using calfactant suspension obtained from vials prescribed for infants who had received their dose in the delivery room or the neonatal intensive care unit (NICU). After initial vial entry, test vials were stored in the NICU pharmacy satellite under refrigeration (temperature range 2.2-7.2 degrees C). Re-entry of test vials and sample removal was performed 12 and 24 hours after initial entry with an 18- or 20-gauge needle. All samples were removed by a neonatal respiratory therapist and placed into 3-mL latex-free, Leur-lok plastic syringes and examined by 3 culture media: MacConkey agar, blood agar, and thioglycollate broth.
Results: A total of 89 surfactant samples from 45 vials were cultured; 45 at a mean time of 13.36 hours (range 11-41) and 44 at a mean time of 25.8 hours (range 22-60) after initial vial entry. These samples represented the technique of multiple respiratory therapists. All samples were negative for bacterial growth at 24 and 48 hours (beta = 0.9).
Conclusions: Results from this short-term sterility study represent an initial step in the evaluation of multiple doses of surfactant from a single-use vial. The data suggest that 1-2 re-entries into a vial of calfactant, within 24 hours after the initial breach, can be a safe and economical method of providing more than a single dose of surfactant to infants weighing <1 kg. We encourage each institution to reproduce these findings before applying this concept to their patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1345/aph.1C463 | DOI Listing |
The emerging of emergent SARS-CoV-2 subvariants has reduced the protective efficacy of COVID-19 vaccines. Therefore, novel COVID-19 vaccines targeting these emergent variants are needed. We designed and prepared CoV072, an mRNA-based vaccine against SARS-CoV-2 Omicron (EG.
View Article and Find Full Text PDFTher Adv Med Oncol
January 2025
Department of General Surgery, The First Affiliated Hospital of Soochow University, No. 899, Pinghai Road, Suzhou, Jiangsu 215006, China.
Despite the availability of multiple treatment options for breast cancer, challenges such as adverse events, drug resistance, and disease progression persist for patients. The identification of human epidermal growth factor receptor 2 (HER2) as an oncogenic driver in a subset of breast cancers, alongside the development of HER2-targeted therapies, has significantly improved the prognosis of HER2-amplified breast cancers. However, therapeutic options remain limited for HER2-overexpressing or HER2-negative breast cancers.
View Article and Find Full Text PDFIndian J Crit Care Med
December 2024
Department of Critical Care Medicine, Tribhuvan University Teaching Hospital, Institute of Medicine, Kathmandu, Bagmati, Nepal.
Aims And Background: Glucocorticoids, vitamin C and thiamine have important biological effects in patients with sepsis and septic shock. Multiple studies have demonstrated the beneficial role of a combination therapy of vitamin C, hydrocortisone and thiamine in patients with sepsis and septic shock in terms of mortality reduction, and increase in the number of days free of ventilators and vasopressors.
Materials And Methods: Patients who had septic shock were assessed for eligibility after intensive care unit (ICU) admission.
Pymetrozine (a pyridine azomethine pesticide) is one of the most commonly and frequently used insecticides. Scanty information is available about the deleterious effects of Pymetrozine on fish especially bighead carp. Hence, the current study investigated chronic toxicological effects of pymetrozine in bighead carp.
View Article and Find Full Text PDFMult Scler
January 2025
Department of Neurology, St. Josef-Hospital, Katholisches Klinikum Bochum, Ruhr-University Bochum, Bochum, Germany.
Background: In Europe, ofatumumab is approved for breastfeeding, but data on its transfer into breast milk and clinical experience are lacking.
Objective: To analyze (1) health, development, and adverse events after live vaccination of ofatumumab-exposed breastfed infants and (2) detectability of ofatumumab in breast milk, and to calculate the relative infant dose (RID) using two methods, the traditional method and a second method considering maternal exposure to multiple ofatumumab doses and extended collection period.
Methods: In this observational study, clinical data were collected by standardized telephone interviews up to 2 years postpartum.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!